Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 6.81%2.68B | 5.29%2.53B | 4.92%2.26B | 9.91%9.63B | 6.27%2.56B | 12.15%2.51B | 10.89%2.4B | 10.75%2.15B | 7.79%8.76B | 9.80%2.41B |
| Operating revenue | 7.05%2.66B | 5.25%2.5B | 4.60%2.23B | 9.87%9.52B | 6.13%2.53B | 12.16%2.48B | 10.86%2.38B | 10.77%2.13B | 7.95%8.66B | 9.87%2.38B |
| Cost of revenue | 7.76%750M | 6.26%764M | 9.53%701M | 8.71%2.78B | 3.12%727M | 11.72%696M | 10.79%719M | 9.97%640M | 8.25%2.56B | 8.13%705M |
| Gross profit | 6.45%1.93B | 4.87%1.77B | 2.97%1.56B | 10.41%6.84B | 7.57%1.83B | 12.32%1.81B | 10.94%1.68B | 11.09%1.51B | 7.60%6.2B | 10.51%1.7B |
| Operating expense | 0.78%1.3B | 4.05%1.31B | 3.86%1.27B | 8.50%4.99B | 2.00%1.22B | 14.63%1.29B | 10.74%1.26B | 6.84%1.22B | 5.24%4.6B | 7.14%1.2B |
| Selling and administrative expenses | -6.47%795M | 7.45%894M | 9.19%867M | 12.99%3.3B | 7.05%820M | 18.88%850M | 17.02%832M | 9.52%794M | 11.12%2.92B | 15.02%766M |
| Research and development costs | 53.42%247M | 1.92%159M | -5.30%143M | 1.99%616M | -4.61%145M | 5.23%161M | 0.00%156M | 5.59%151M | 14.18%604M | 7.80%152M |
| Depreciation amortization depletion | -7.66%253M | -5.19%256M | -6.57%256M | 0.00%1.08B | -8.16%259M | 8.30%274M | 0.37%270M | 0.37%274M | -11.36%1.08B | -9.90%282M |
| -Depreciation and amortization | -7.66%253M | -5.19%256M | -6.57%256M | 0.00%1.08B | -8.16%259M | 8.30%274M | 0.37%270M | 0.37%274M | -11.36%1.08B | -9.90%282M |
| Operating profit | 20.23%636M | 7.28%457M | -0.68%292M | 15.88%1.85B | 20.87%608M | 7.09%529M | 11.52%426M | 33.03%294M | 15.03%1.6B | 19.48%503M |
| Net non-operating interest income (expenses) | -17.11%-397M | -32.16%-452M | 7.80%-319M | -4.07%-1.36B | 7.87%-328M | -1.80%-339M | -9.62%-342M | -14.95%-346M | 10.21%-1.3B | -18.27%-356M |
| Non-operating interest income | 114.29%15M | 62.50%13M | 22.22%11M | 26.92%33M | 28.57%9M | 16.67%7M | 14.29%8M | 50.00%9M | 85.71%26M | 16.67%7M |
| Non-operating interest expense | 19.08%412M | 32.86%465M | -7.04%330M | 4.52%1.39B | -7.16%337M | 2.06%346M | 9.72%350M | 15.64%355M | -9.29%1.33B | 18.24%363M |
| Other net income (expenses) | 90.05%-21M | 475.00%135M | -17.65%-20M | 51.74%-332M | 53.90%-71M | 56.67%-211M | -500.00%-36M | 69.64%-17M | -882.86%-688M | 67.71%-154M |
| Gain on sale of security | ---7M | -172.73%-30M | 73.33%-4M | 9.62%-47M | -50.00%-21M | ---- | 47.62%-11M | -50.00%-15M | -550.00%-52M | -16.67%-14M |
| Special income (charges) | 93.36%-14M | 854.55%166M | -700.00%-16M | 55.12%-285M | 64.29%-50M | 56.04%-211M | -170.97%-22M | 95.65%-2M | -2,251.85%-635M | 67.37%-140M |
| -Less:Restructuring and mergern&acquisition | -146.43%-13M | -55.56%4M | -190.00%-9M | -64.83%51M | -91.49%4M | -49.09%28M | 350.00%9M | -75.61%10M | 130.16%145M | 1,466.67%47M |
| -Less:Impairment of capital assets | --1M | --0 | --0 | -94.70%29M | -74.73%23M | --0 | -86.49%5M | -92.31%1M | -34.80%547M | -85.37%91M |
| -Less:Other special charges | -82.98%32M | -1,988.89%-170M | 600.00%25M | 498.15%215M | 2,200.00%23M | 683.33%188M | 112.68%9M | 37.50%-5M | 93.83%-54M | 100.50%1M |
| -Gain on sale of property,plant,equipment | 20.00%6M | --0 | --0 | 233.33%10M | --0 | 0.00%5M | 200.00%1M | --4M | --3M | ---1M |
| Other non-operating income (expenses) | ---- | 66.67%-1M | ---- | ---- | ---- | ---- | -200.00%-3M | ---- | 97.14%-1M | --0 |
| Income before tax | 1,138.10%218M | 191.67%140M | 31.88%-47M | 142.82%167M | 3,085.71%209M | 93.56%-21M | -39.24%48M | 49.26%-69M | -202.33%-390M | 98.04%-7M |
| Income tax | -47.89%37M | -75.51%12M | 387.50%39M | 8.14%239M | 177.50%111M | 26.79%71M | -5.77%49M | -89.04%8M | 166.27%221M | -24.53%40M |
| Earnings from equity interest net of tax | ||||||||||
| Net income | 296.74%181M | 12,900.00%128M | -11.69%-86M | 88.22%-72M | 308.51%98M | 75.92%-92M | -103.70%-1M | 63.16%-77M | -188.21%-611M | 88.54%-47M |
| Net income continuous operations | 296.74%181M | 12,900.00%128M | -11.69%-86M | 88.22%-72M | 308.51%98M | 75.92%-92M | -103.70%-1M | 63.16%-77M | -188.21%-611M | 88.54%-47M |
| Noncontrolling interests | 128.57%2M | -81.82%-20M | -115.38%-28M | -36.84%-26M | 162.50%5M | -75.00%-7M | -1,200.00%-11M | -62.50%-13M | -246.15%-19M | -8M |
| Net income attributable to the company | 310.59%179M | 1,380.00%148M | 9.38%-58M | 92.23%-46M | 338.46%93M | 77.51%-85M | -61.54%10M | 68.16%-64M | -163.11%-592M | 90.49%-39M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 310.59%179M | 1,380.00%148M | 9.38%-58M | 92.23%-46M | 338.46%93M | 77.51%-85M | -61.54%10M | 68.16%-64M | -163.11%-592M | 90.49%-39M |
| Diluted earnings per share | 308.70%0.48 | 1,233.33%0.4 | 5.88%-0.16 | 91.98%-0.13 | 327.27%0.25 | 77.67%-0.23 | -57.14%0.03 | 69.09%-0.17 | -161.29%-1.62 | 90.27%-0.11 |
| Basic earnings per share | 308.70%0.48 | 1,233.33%0.4 | 5.88%-0.16 | 91.98%-0.13 | 327.27%0.25 | 77.67%-0.23 | -57.14%0.03 | 69.09%-0.17 | -161.29%-1.62 | 90.27%-0.11 |
| Dividend per share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.